Breaking Finance News

BREAKING- Pfizer Not Planning to Bid for Onyx

According to Reuters, Pfizer (NYSE: PFE) is not planning to bid for Onyx Pharmaceuticals (NASDAQ: ONXX)

On Tuesday, Breaking Finance News reported that as many as five companies may be interested in acquiring the company. Onyx Pharmaceuticals is a $9.7 billion company that is best known for its drug, Nexavar for the treatment of liver cancer. It’s other notable drug, Kyprolis is indicated for the treatment of multiple myeloma.

[stock-tools exchange="NYSE" symbol="PFE" image_height="230" image_width="350"]

Disclosure: At the time of this writing, the author had no position in the company mentioned.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.